Methyldopa
As of the edition of 20 October 2026, Methyldopa is a small molecule: marketed, first approved in 1962 (ES); acts on ADRA2A, ADRA2B and ADRA2C.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2010
- Kind
- Small molecule
- Brand name
- Aldomet
- First approved
- 1 June 1962 (ES)
- Approvals on record
- 16 in 5 regions
- Holder of the most recent approval
- ASPEN PHARMA INDÚSTRIA FARMACÊUTICA LTDA; 5 holders in all
- Registered trials
- 13, 2 stopped early
- Disease areas
- Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive; Hormones; Immune system; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Methyldopa.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 3 | 0 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 3 | 1 | 0 | 2 |
| Phase 4 | 4 | 2 | 0 | 0 |
| All trials | 13 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Chartwell Rx Sciences | Acquired holder | 2021 to now |
| Merck & Co. | Applicant |